Abstract
Purpose To compare ocular tolerability of dorzolamide 2%, brinzolamide 1%, and placebo given three times daily.
Methods A prospective, double-masked, three-centre, crossover comparison in which 25 ocular hypertensive or primary-open angle glaucoma subjects were randomized to receive dorzolamide, brinzolamide, or placebo three times daily for 3 days. Intraocular pressure, visual acuity, a visual analogue scale, and ocular and systemic symptom queries were completed at the end of each period.
Results After chronic dosing, there was a significant difference in ocular pain on the visual analogue scale among the groups at the 10-s postinstillation time point with dorzolamide having the highest level (22.5±28.9) compared to brinzolamide (5.0±8.7) or placebo (3.2±10.4) (P=0.0006). No differences between groups were observed preinstillation nor following dosing at 3 or 10-min postinstillation. On the initial instillation, the 10-s postinstillation pain was rated as 43.3±77.1, which was significantly higher than after chronic dosing (P=0.017). On the ocular symptom query, dorzolamide had the highest incidence of burning/stinging and redness compared to the other groups, but was generally characterized as mild. There were no significant differences in the visual acuity at any time point.
Conclusions This study suggests that subjects treated with dorzolamide suffer more ocular pain upon instillation compared to brinzolamide or placebo. However, pain symptoms are fewer following chronic dosing and are generally characterized as mild.
Similar content being viewed by others
Login or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Lippa EA, Carlson LE, Ehinger B, Eriksson LO, Finnstrom K, Holmin C et al. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol 1992; 110: 495.
Lippa EA, Schuman JS, Higginbotham EJ, Kass MA, Weinrib RN, Skuta GL et al. MK-507 versus sezolamide: a comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology 1991; 98(3): 308.
Wilkerson M, Cyrlin M, Lippa EA, Esposito D, Deasy D, Panebianco D et al. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol 1993; 111: 1343.
Kitazawa Y, Azuma I, Iwata K, Tsukahara S, Shioes Y, Araie M et al. Dorzolamide, a topical carbonic anhydrase inhibitor: a two-week dose response study in patients with glaucoma or ocular hypertension. J Glaucoma 1994; 3: 275–279.
Strahlman E, Tipping R, Vogel R, the International Dorzolamide Study Group. A double masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. Arch Ophthalmol 1995; 113: 1009–1016.
Laibovitz R, Strahlman ER, Barber BL, Strohmaier KM . Comparison of quality of life and patient preference of dorzolamide and pilocarpine as adjunctive therapy to timolol in the treatment of glaucoma. J Glaucoma 1995; 4: 306–313.
Shin DH, the Brinzolamide Adjunctive Therapy Study Group. A triple-masked, placebo-controlled, adjunctive therapy study of the efficacy and safety of TID-dosed brinzolamide 1.0% compared to TID-dosed placebo when used adjunctively to timolol 0.5%. Invest Ophthalmol Vis Sci (Suppl) 1997; 38: 2605.
Camras CB, the Brinzolamide Primary Therapy Study Group. A triple-masked, primary therapy study of the efficacy and safety of BID and TID-dosed brinzolamide 1% compared to TID-dosed dorzolamide 2% and BID-dosed timolol 0.5%. Invest Ophthalmol Vis Sci (Suppl) 1997; 38: 2605.
Stewart R, the Brinzolamide Comfort Study Group. The ocular comfort of the TID-dosed brinzolamide 1.0% compared to TID-dosed dorzolamide 2.0% in patients with primary open-angle glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci (Suppl) 1997; 38: 2603.
Scoville B, Krieglstein GK, Then E, Yokoyama S, Yokoyama T . Measuring drug-induced eye irritation: a simple new clinical assay. J Clin Pharmacol 1985; 25: 210–218.
Price DD, McGrath PA, Rafii A, Buckingham B . The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain 1983; 17: 45–56.
Book SA . Essentials of Statistics. McGraw Hill Book Company: New York, 1978, pp 117–122, 205–215.
Rosner B . Fundamentals of Biostatistics. Duxbury Press: Boston, 1982, pp 336–341.
Siegel S . Nonparametric Statistics for the Behavioral Sciences. McGraw Hill Book Company: New York, 1956, pp 63–67.
Silver LH, the Brinzolamide Primary Therapy Study Group. Clinical efficacy and safety of brinzolamide (Azopt™), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 1988; 126: 400–408.
Michaud JE, Friren B, the International Brinzolamide Adjunctive Study Group. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 132: 235–243.
Barnebey H, Kwok SY . Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther 2000; 22: 1204–1212.
Sriwatanakul K, Kelvie W, Lasagna L, Calimlim JF, Weis OF, Mehta G . Studies with different types of visual analog scales for measurement of pain. Clin Pharmacol Ther 1983; 34(2): 234–239.
Collins SL, Moore RA, McQuay HJ . The visual analogue pain intensity scale: what is moderate pain in millimeters? Pain 1997; 72(1–2): 95–97.
Curtis P, Gartman LA, Green DB . Utilization of ketorolac tromethanine for control of severe odontogenic pain. J Endod 1994; 20(9): 457–459.
Seymour RA, Kelly PJ, Hawesford JE . The efficacy of ketoprofen and paracetamol (acetaminophen) in postoperative pain after third molar surgery. Br J Clin Pharmacol 1996; 41: 581–585.
Stubhaug A, Grimstad J, Breivik H . Lack of analgestic effect of 50 and 100 mg oral tramadol after orthopedic surgery: a randomized, double-blind, placebo and standard active drug comparison. Pain 1995; 62(1): 111–118.
Author information
Authors and Affiliations
Corresponding author
Additional information
This study was sponsored by an unrestricted grant from Merck, Inc. None of the authors have a proprietary interest in Merck or in any of the commercial products mentioned in the paper.
Rights and permissions
About this article
Cite this article
Stewart, W., Day, D., Stewart, J. et al. Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs placebo in primary open-angle glaucoma and ocular hypertension subjects. Eye 18, 905–910 (2004). https://doi.org/10.1038/sj.eye.6701353
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.eye.6701353
Keywords
This article is cited by
-
X-linked retinoschisis maculopathy treated with topical dorzolamide, and relationship to genotype
Eye (2011)
-
Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension
Graefe's Archive for Clinical and Experimental Ophthalmology (2011)
